Celltrion’s Remsima announces dismissal of issuing ban suit of additional indication

Celltrion has started to enlarge its share in the Canadian market. On the 13^th, Celltrion announced dismissal of the suit filed by Janssen to the Canadian court last September in regards to issuing ban of addition indication of inflammatory bowel disease(IBD) on Remsima(local name: Inflectra).

Celltrion acquired sales approval of ‘Remsima,’ a treatment for rheumatoid arthritis, from the Health...